Objective. To verify the effects of a pill containing drospirenone on the surrogate markers of arterial function and to evaluate the possible improvements induced by the addition of l-arginine. Design. A prospective, placebo controlled, randomised, pilot study. Setting. University of Bologna. Population. Twenty-eight young women with PCOS. Methods. Random submission to: drospirenone + ethinylestradiol+ a placebo (Group I; n = 15) or drospirenone + ethinylestradiol + oral l-arginine (4 g x 2/daily) (Group II, n = 13). Main outcome measures. Medical examination; blood measurement of nitrites/nitrates, biochemical and hormonal parameters; ultrasonographic analysis and colour Doppler evaluation of uterine, stromal ovarian and ophthalmic arteries; analysis of brachial artery flow-mediated vasodilatation; and 24-h ambulatory blood pressure monitoring. The above parameters were evaluated before and after 6 months. Results. The low dose oral contraceptive containing drospirenone favoured a pre-hypertensive state The l-arginine supplementation increased the circulating levels of nitrites/nitrates and improved the endothelium-dependent vasodilatation counteracting the negative effect of the contraceptive pill. Conclusions. Although, the present pilot study was conducted in a limited number of patients, it seems that the l-arginine co-treatment may improve the long-term side effects of the pill reducing the risk of cardiovascular diseases.

l-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study / C., Battaglia; F., Mancini; B., Battaglia; Facchinetti, Fabio; P. G., Artini; S., Venturoli. - In: GYNECOLOGICAL ENDOCRINOLOGY. - ISSN 0951-3590. - STAMPA. - 26 issue 12:(2010), pp. 861-868. [10.3109/09513590.2010.501882]

l-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study.

FACCHINETTI, Fabio;
2010-01-01

Abstract

Objective. To verify the effects of a pill containing drospirenone on the surrogate markers of arterial function and to evaluate the possible improvements induced by the addition of l-arginine. Design. A prospective, placebo controlled, randomised, pilot study. Setting. University of Bologna. Population. Twenty-eight young women with PCOS. Methods. Random submission to: drospirenone + ethinylestradiol+ a placebo (Group I; n = 15) or drospirenone + ethinylestradiol + oral l-arginine (4 g x 2/daily) (Group II, n = 13). Main outcome measures. Medical examination; blood measurement of nitrites/nitrates, biochemical and hormonal parameters; ultrasonographic analysis and colour Doppler evaluation of uterine, stromal ovarian and ophthalmic arteries; analysis of brachial artery flow-mediated vasodilatation; and 24-h ambulatory blood pressure monitoring. The above parameters were evaluated before and after 6 months. Results. The low dose oral contraceptive containing drospirenone favoured a pre-hypertensive state The l-arginine supplementation increased the circulating levels of nitrites/nitrates and improved the endothelium-dependent vasodilatation counteracting the negative effect of the contraceptive pill. Conclusions. Although, the present pilot study was conducted in a limited number of patients, it seems that the l-arginine co-treatment may improve the long-term side effects of the pill reducing the risk of cardiovascular diseases.
26 issue 12
861
868
l-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study / C., Battaglia; F., Mancini; B., Battaglia; Facchinetti, Fabio; P. G., Artini; S., Venturoli. - In: GYNECOLOGICAL ENDOCRINOLOGY. - ISSN 0951-3590. - STAMPA. - 26 issue 12:(2010), pp. 861-868. [10.3109/09513590.2010.501882]
C., Battaglia; F., Mancini; B., Battaglia; Facchinetti, Fabio; P. G., Artini; S., Venturoli
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/645074
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact